



202 – 20 De Boers Dr,
Toronto ON, M3J 0H1
Phone: (416) 630-7272

Email: info@supreme.ca
Website: www.supreme.ca

Listed on the CSE under the symbol ("SL")

SUPREME OBTAINS MMPR LICENSE TO CULTIVATE MEDICAL MARIJUANA

March 11, 2016, Toronto, ON – Supreme Pharmaceuticals Inc. (the “Company” or “Supreme”) (SPRWF – OTC) (“SL” – CSE) is pleased to announce its wholly-owned subsidiary, Advanced Medical Marihuana Canada (“AMMCan”) has been granted a license to cultivate medical marijuana pursuant to the *Marihuana for Medical Purposes Regulations* (the “MMPR”).

About Supreme

Supreme is a Canadian publically traded company committed to becoming a leading supplier of affordable medical cannabis through its wholly-owned subsidiary AMMCan. AMMCan is a federally licensed producer of medical marijuana pursuant to the MMPR operating a 7 Acre hybrid greenhouse facility. The Hybrid Greenhouse combines the best technology of indoor production with the efficiencies and sustainability of a greenhouse, in a single large-format production footprint. Please visit www.supreme.ca and www.ammcan.com for more information.

Contact Information

Investor Relations

202 – 20 De Boers Dr, Toronto ON

M3J 0H1

Phone: (416) 630-7272

Email: info@supreme.ca

Website: www.supreme.ca

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These risks and uncertainties include, but are not limited to, the Company's ability to satisfy the conditions associated with its cultivation license, the Company's ability to obtain a sales license and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com. This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.